About Atsena Therapeutics
Atsena Therapeutics develops subretinal AAV gene therapies for inherited retinal dystrophies including GUCY2D-LCA1 and RPGR-associated X-linked retinitis pigmentosa.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Atsena Therapeutics. Response typically within 48 hours.
